Visible Particles, Drug Shortages, DSCSA Spotlighted In CDER’s 2020 Quality/GMP Guidance Agenda
The US FDA plans to issue new guidance this year on visible particle inspections, drug shortage risk management plans, and several guidances related to DSCSA implementation, one on identifying trading partners and the other on establishing verifications systems.
You may also be interested in...
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.